Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q53106572)
Watch
English
New anti-HCV drug combinations: who will benefit?
scientific article published on 14 August 2017
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
title
New anti-HCV drug combinations: who will benefit?
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
author name string
Peter Ferenci
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
publication date
14 August 2017
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
published in
Lancet Infectious Diseases
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
volume
17
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
issue
10
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
page(s)
1008-1009
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
cites work
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS1473-3099%2817%2930486-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S1473-3099(17)30486-3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
PubMed publication ID
28818545
1 reference
stated in
Europe PubMed Central
PubMed publication ID
28818545
retrieved
11 May 2018
reference URL
http://europepmc.org/abstract/MED/28818545
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit